Advertisement

HIV Care Today


Should You Answer Medical Questions From Clinicians You Don't Know About Patients You've Never Seen?
By Paul E. Sax, M.D.
July 9, 2017

This email popped into my inbox the other day from a person I've never met:

Hi Dr. Sax,
I do mostly hospital-based ID in Pennsylvania, and was consulted on a newly diagnosed HIV patient with CD4 10, viral load 210,000, and lymphoma. I started him on Truvada and dolutegravir, which is going well so far. Because he complained of blurred vision, he had an ophtho evaluation yesterday which showed CMV retinitis. My drug-interaction checker says I can't use valganciclovir with either tenofovir or abacavir, and if I replace the Truvada with a boosted PI, it will interact with his chemotherapy. What should I do for his ART?
Thanks so much.
Marie

Read more …



The Curious Case of M184V, Part 1
By Paul E. Sax, M.D.
May 21, 2017

Most of you are clinicians -- doctors, nurses, PAs, PharmDs. A smaller proportion are researchers, lab-oriented types who wandered over here unexpectedly after an errant search, expecting the latest in CRISPR-Cas9 gene editing and instead getting an ID Link-o-Rama, a rumination on vintage medical photos, and a mysteriosis about listeriosis.

Read more …


Celebrating the Invaluable Knowledge and Expertise of ID Specialist Pharm.D.'s
By Paul E. Sax, M.D.
April 30, 2017

Since expression of gratitude makes you happier -- hey, I read it on the internet -- and whining does the reverse, I've decided to turn what was going to be a typical rant about dealing with insurance companies into an expression of thanks to a remarkable group of professionals.

Read more …


Mark Wainberg and the Enduring Importance of 3TC
By Paul E. Sax, M.D.
April 16, 2017

Last week, the HIV/ID research world lost one of its leaders and pioneers when Dr. Mark Wainberg unexpectedly died. An astute, thoughtful virologist -- and a warm, engaging person -- he led the HIV research program at McGill University in Montreal for years, contributing to the field both through his research and patient advocacy. A strong voice in the effort to expand HIV therapy to Africa in the early 2000s, Mark was also a vocal critic of HIV denialism.

Read more …


HIV and Hepatitis C Are No Longer the Most Serious Infectious Threats to People Who Inject Drugs
By Paul E. Sax, M.D.
March 25, 2017

I had dinner with my daughter Mimi the other evening, and was ruminating about how things have changed since I started work as an Infectious Diseases doctor around 25 years ago.

Read more …


Improving Outcomes With ID Consultation: Three More Papers for the Collection
By Paul E. Sax, M.D.
February 26, 2017

Several years ago, one of my very brilliant colleagues posed an interesting question.

Why do ID specialists even exist?

Read more …


Really Rapid Review -- CROI 2017, Seattle
By Paul E. Sax, M.D.
February 19, 2017

The Conference on Retroviruses and Opportunistic Infections (CROI) returned to Seattle this past week for its 24th meeting. It's the 4th time CROI has been held in Seattle, an excellent city for a meeting of this size, which includes "only" 4200 people. The convention center is pleasant and user-friendly -- big but not cavernous, actually encourages interactions with colleagues -- and there are numerous hotels and restaurants within walking distance, plus more Starbucks per square foot than any place on the planet.

Read more …


In the Eye of the Storm: One Doctor's 30-Year Journey Through the AIDS Crisis
By Ross A. Slotten, M.D.
January/February 2017

A couple of years ago, I reread some journals I'd kept during the worst years of the AIDS epidemic. I hadn't looked at them in more than a decade and was surprised not only by their vividness but also by the rawness of their content. They brought back memories of a time I'd almost forgotten or, rather, repressed because of the intense sadness they evoked. As a doctor, I was taught to keep an emotional distance from my patients. Too much emotion clouds one's judgment. But how does one keep an emotional distance from men who were like me at the time, young and gay and who ought to have had more tomorrows than yesterdays?

Read more …


How to Make Preventing Heart Disease in HIV Fun and Exciting: The REPRIEVE Trial
By Paul E. Sax, M.D.
February 13, 2017

The people researching cardiovascular disease in HIV have quite the challenge.

Because when you think about it for a second, we HIV treaters are a pretty spoiled bunch when it comes to therapeutic success.

Read more …

 1  |  2  |  3  |  …  |  22  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.